Different patterns of expansion, contraction and memory differentiation of HIV-1 Gag-specific CD8 T cells elicited by adenovirus type 5 and modified vaccinia Ankara vaccines

Vaccine

Volumn 29, Issue 33, 2011, Pages 5399-5406

  Pillai, Vinod Kumar Bhaskara ^a   Kannanganat, Sunil ^a   Penaloza MacMaster, Pablo ^a   Chennareddi, Lakshmi ^a   Robinson, Harriet L ^a,b   Blackwell, Jerry ^a   Amara, Rama Rao ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Research and Development   (United States)

Author keywords

Ad5; CD8 T cells; MVA; Viral vectors

Indexed keywords

ADENOVIRUS TYPE 5 VECTOR; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; L SELECTIN; MODIFIED VACCINIA VIRUS ANKARA VECTOR; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CYTOKINE PRODUCTION; EFFECTOR CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNIZATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; DRUG CARRIERS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VECTORS; IMMUNOLOGIC MEMORY; L-SELECTIN; MICE; MICE, INBRED BALB C; T-LYMPHOCYTE SUBSETS; VACCINIA VIRUS;

EID: 79960384537     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.05.083     Document Type: Article

References (44)

1. Kaech S.M., Wherry E.J., Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002, 2(4):251-262.
2. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107(June (12)):4781-4789.
3. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13(July (7)):843-850.
4. Kannanganat S., Ibegbu C., Chennareddi L., Robinson H.L., Amara R.R. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 2007, 81(August (16)):8468-8476.
5. Kannanganat S., Kapogiannis B.G., Ibegbu C., Chennareddi L., Goepfert P., Robinson H.L., et al. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J Virol 2007, 81(November (21)):12071-12076.
6. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401(6754):708-712.
7. Wherry E.J., Teichgraber V., Becker T.C., Masopust D., Kaech S.M., Antia R., et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003, 4(March (3)):225-234.
8. Vaccari M., Trindade C.J., Venzon D., Zanetti M., Franchini G. Vaccine-induced CD8+ central memory T cells in protection from simian AIDS. J Immunol 2005, 175(September (6)):3502-3507.
9. Lauvau G., Vijh S., Kong P., Horng T., Kerksiek K., Serbina N., et al. Priming of memory but not effector CD8 T cells by a killed bacterial vaccine. Science 2001, 294(November (5547)):1735-1739.
10. Manjunath N., Shankar P., Wan J., Weninger W., Crowley M.A., Hieshima K., et al. Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes. J Clin Invest 2001, 108(September (6)):871-878.
11. Langenkamp A., Messi M., Lanzavecchia A., Sallusto F. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 2000, 1(October (4)):311-316.
12. Iezzi G., Scheidegger D., Lanzavecchia A. Migration and function of antigen-primed nonpolarized T lymphocytes in vivo. J Exp Med 2001, 193(April (8)):987-993.
13. Bouneaud C., Garcia Z., Kourilsky P., Pannetier C. Lineage relationships, homeostasis, and recall capacities of central- and effector-memory CD8 T cells in vivo. J Exp Med 2005, 201(February (4)):579-590.
14. Marzo A.L., Klonowski K.D., Le Bon A., Borrow P., Tough D.F., Lefrancois L. Initial T cell frequency dictates memory CD8+ T cell lineage commitment. Nat Immunol 2005, 6(August (8)):793-799.
15. Jabbari A., Harty J.T. Secondary memory CD8+ T cells are more protective but slower to acquire a central-memory phenotype. J Exp Med 2006, 203(April (4)):919-932.
16. Badovinac V.P., Haring J.S., Harty J.T. Initial T cell receptor transgenic cell precursor frequency dictates critical aspects of the CD8(+) T cell response to infection. Immunity 2007, 26(June (6)):827-841.
17. Sarkar S., Teichgraber V., Kalia V., Polley A., Masopust D., Harrington L.E., et al. Strength of stimulus and clonal competition impact the rate of memory CD8 T cell differentiation. J Immunol 2007, 179(November (10)):6704-6714.
18. Schluns K.S., Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 2003, 3(April (4)):269-279.
19. Pulendran B., Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006, 124(February (4)):849-863.
20. Querec T., Bennouna S., Alkan S., Laouar Y., Gorden K., Flavell R., et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 2006, 203(February (2)):413-424.
21. Wyatt L.S., Earl P.L., Liu J.Y., Smith J.M., Montefiori D.C., Robinson H.L., et al. Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component. AIDS Res Hum Retroviruses 2004, 20(June (6)):645-653.
22. Huang Y., Kong W.P., Nabel G.J. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J Virol 2001, 75(10):4947-4951.
23. Yao Q., Bu Z., Vzorov A., Yang C., Compans R.W. Virus-like particle and DNA-based candidate AIDS vaccines. Vaccine 2003, 21(January (7-8)):638-643.
24. Lefrancois L., Lycke N. Current protocols in immunology 1996, John Wiley & Sons, Inc., New Jersy.
25. Ganguly S, Manicassamy S, Blackwell J, Pulendran B, Amara RR. Adenovirus type 5 induces vitamin A-metabolizing enzymes in dendritic cells and enhances priming of gut-homing CD8 T cells. Mucosal Immunol 2011, February 2.
26. Garnett C.T., Erdman D., Xu W., Gooding L.R. Prevalence and quantitation of species C adenovirus DNA in human mucosal lymphocytes. J Virol 2002, 76(November (21)):10608-10616.
27. Chantrey J., Meyer H., Baxby D., Begon M., Bown K.J., Hazel S.M., et al. Cowpox: reservoir hosts and geographic range. Epidemiol Infect 1999, 122(June (3)):455-460.
28. Shiver J.W., Fu T., Chen L., Casimiro D., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency virus immunity. Nature 2002, 415:331-335.
29. Casimiro D.R., Chen L., Fu T.-M., Evans R.K., Caulfield M.J., Davies M.-E., et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003, 77(June (11)):6305-6313.
30. Santra S., Seaman M.S., Xu L., Barouch D.H., Lord C.I., Lifton M.A., et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 2005, 79(May (10)):6516-6522.
31. Liu J., O/'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457(7225):87-91.
32. Murali-Krishna K., Altman J.D., Suresh M., Sourdive D.J., Zajac A.J., Miller J.D., et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998, 8(2):177-187.
33. Harrington L.E., Most Rv R., Whitton J.L., Ahmed R. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J Virol 2002, 76(7):3329-3337.
34. Nigam P., Earl P.L., Americo J.L., Sharma S., Wyatt L.S., Edghill-Spano Y., et al. DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge. Virology 2007, 366(September (1)):73-83.
35. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., et al. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003, (August):1-7. 10.1038/nm917.
36. Crotty S., Felgner P., Davies H., Glidewell J., Villarreal L., Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003, 171(November (10)):4969-4973.
37. Amara R.R., Nigam P., Sharma S., Liu J., Bostik V. Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J Virol 2004, 78(April (8)):3811-3816.
38. Maeda K., West K., Hayasaka D., Ennis F.A., Terajima M. Recombinant adenovirus vector vaccine induces stronger cytotoxic T-cell responses than recombinant vaccinia virus vector, plasmid DNA, or a combination of these. Viral Immunol 2005, 18(4):657-667.
39. Tatsis N., Fitzgerald J.C., Reyes-Sandoval A., Harris-McCoy K.C., Hensley S.E., Zhou D., et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 2007, 110(September (6)):1916-1923.
40. Hanke T., McMichael A.J., Dennis M.J., Sharpe S.A., Powell L.A., McLoughlin L., et al. Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine 2005, 23(February (12)):1507-1514.
41. Wherry E.J., Blattman J.N., Murali-Krishna K., van der Most R., Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003, 77(April (8)):4911-4927.
42. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001, 292(April):69-74.
43. Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J., et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004, 172(May (10)):6290-6297.
44. Roberts D.M., Nanda A., Havenga M.J., Abbink P., Lynch D.M., Ewald B.A., et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 2006, 441(May (7090)):239-243.